Open in PodwiseOpen

Podcast cover

BioSpace · Business

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes

Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter

From Two Trials to One, Sponsors Face a Higher Standard

Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data

Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead

From Grants to Family Offices: Building a Unified Financing Strategy in Biotech

UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More

ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer

Redefining Obesity Treatment Beyond GLP-1 Limits

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

As FDA Moves Away From Animal Testing, AI and Organoids Can Shine

Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News

Programmable RNA 2.0: Beyond the First mRNA Revolution

Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs

Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides

Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More

From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM

JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return

Page 4

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise